[Cancer and therapy for it--from gynecological standpoints].
Life phenomena have been studied scientifically for more than 160 years. Meanwhile many excellent technology and methodology which human race created have been used in the field of medicine. Analytical research for the constitution of life and impediments to life has remarkably advanced. Pathophysiology of many diseases has been clarified and reasonable and effective treatment for disorders has been organized. Many disorders which showed high mortality in the past are now listed as one of minor diseases in the textbook. However, the disease which cause is unclear and which deprives human race of life still exists. That is "CANCER". The society of medicine devotes the greatest energies to abolish the cancer. I am going to talk about the physiological characteristics of "the cancer in human race" from the gynecological standpoints and to present some facts of studies about the therapy for cancer in our department. I. Evolution of human and cancer 1. Life of species and life of individuals In the development from uni-nuclear cell creature to multicellular entity, to give new generation sexual reproduction was out-lasted for the adaptation to environment advantageously after the spread out of mutant gene in this entity. With this evolution, a living creature divided its cells into two types. One is somatic cells which would die in certain period and the other is germ cells which would not die on principle in good environment. In short well evolved living entity clearly established individual life span for the first time and its constituent, that is somatic cells demonstrated "AGEING" phenomena regulating life span.(ABSTRACT TRUNCATED AT 250 WORDS)
Sugawa
T
T
Department of Obstetrics and Gynecology, Osaka City University Medical School.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000375:Aging / Q000473:pathology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005075:Biological Evolution; D001798:Blood Proteins / Q000502:physiology; D002455:Cell Division; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007108:Immune Tolerance; D007167:Immunotherapy; D008017:Life Expectancy; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000188:drug therapy; D012074:Remission Induction
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D001798:Blood Proteins; C007627:erythropoiesis inhibiting factors; D002945:Cisplatin